HC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $20

Benzinga Newsdesk www.benzinga.com Negative 62.1%

Neg 62.1% Neu 0% Pos 0%

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $25 to $20.